SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a ...

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA™ ...

Levonorgestrel intrauterine system is safe and efficacious for contraception over a 5-year period, data from a phase III trial found. Pearl Indices, or the number of unintentional pregnancies, for ...

IUD insertion tube. A levonorgestrel 52-mg intrauterine system was found to be safe and effective for pregnancy prevention. A levonorgestrel 52-mg intrauterine system (IUS) was found to be safe and ...

First-time users of the long-acting contraceptive levonorgestrel-releasing intrauterine system (LNG-IUS) experience a 15%-23% of reduction in incident depression with the use of low- vs high-dose ...

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...

Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mirena (levonorgestrel-releasing intrauterine system; Bayer), to extend the indication to up to 6 ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

WHIPPANY, N.J., Oct. 21, 2019 /PRNewswire/ -- Bayer, a leader in women's healthcare, announced today the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug ...

U.S. FDA APPROVES BAYER'S SKYLA™(LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 13.5 mg FOR PREVENTION OF PREGNANCY FOR UP TO THREE YEARS Wayne, NJ, January 9, 2013 – Bayer HealthCare Pharmaceuticals ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that ...